BIOTECH TEMPERATURE RISES
Investors are showing classic symptoms of biotech fever.
They’re seizing on good news about drug trials, cheering new drug-related news and buying shares contagiously…

Biotech is benign
Europe’s continued blocking of GM imports is illegal, unjustified and founded on ignorance.

Science and Law: Swapping the lab for the law
For scientists who want a career in law, the options are greater than ever – and some don’t even involve going back to school

Biotech sector keeps surging / Cancer drug news and FDA approvals create optimism
Industry observers say the sector’s sea change from pessimism to optimism comes from two sources: Good news about experimental cancer drugs from a major scientific meeting this month; and a set of recent approvals by the Food and Drug Administration, whose new leadership is seen as more company-friendly.

Early stage biotechnology collaborations
The range of deals an early stage biotechnology company may enter into is wide (see box ‘What is an early stage biotechnology collaboration?’). This chapter examines, by reference to a few of the types of agreements that an early stage company may enter into, some of the key intellectual property (IP) and other legal issues that arise when undertaking such deals

FDA chief looks to speed diabetes, obesity drugs
Mark McClellan, commissioner of the Food and Drug Administration, said he wants to apply a fast-track review process normally reserved for drugs for terminal cancer and AIDS patients to drugs for diabetes and obesity.

Pfizer sues over counterfeit Lipitor
Pfizer Inc. said Tuesday it was suing two companies connected to counterfeit versions of its cholesterol fighter, Lipitor, the world’s top-selling prescription medicine.

The ImClone Story: A Hyped Drug, a Tainted Icon
It was, in retrospect, a festival of hype emblematic of the boom years, when technology stocks seemed to have nowhere to go but up.

Five Hurdles for Biotech
The science is hot and the stocks are up. Here’s what’s needed to deliver on the promise.

San DNAgo
Thanks to a fruitful partnership of academia and private enterprise, a vibrant biotech industry keeps on replicating itself.